SKYE
Skye Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.92
+7.87%Aug 24, 2026, 00:00 UTC
Skye Bioscience entered into a securities purchase agreement to sell up to $22 million of its common and non-voting common stock to Redmile Biopharma Investments III, L.P. over a three-year term, and issued a warrant to purchase up to $5 million of shares.
Aug 19, 2026, 00:00 UTC
Skye Bioscience, Inc. received a notice from NASDAQ on August 18, 2026, stating that the company no longer complies with the minimum stockholders' equity requirement of Rule 5550(b)(1), and must achieve at least $2,500,000 in stockholders' equity by October 2, 2026, to regain compliance.
Aug 14, 2026, 13:33 UTC
Skye Bioscience and Redx Pharma announced concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing healthcare institutional investors.
Source:Aug 14, 2026, 13:33 UTC
Skye Bioscience and Redx Pharma entered into a definitive transaction agreement to combine, with the combined company to operate as Fibrx Therapeutics and trade on Nasdaq.